Geon Investment
14 Daewangpangyo-ro 645beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13487, South Korea
Overview
Geon Investment Inc. is a venture capital firm specializing in expansion stage and growth capital. For venture investments, the firm considers investments in following industries: Digital and mobile contents, biotechnology, mobile/online game and movie/music contents. Primarily invests between KRW 500 million ($0.5 million) and KRW 2 billion ($2 million) in equity per transaction in companies. The firm was established in 2009 and is based in Seongnam, South Korea.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Financial Services
Investment portfolio
- Neuraly
Participated · Series A · Jul 2018
Neuraly is focused on developing disease‑modifying agents for neurodegenerative disorders, primarily Parkinson’s and Alzheimer’s disease. Its lead program, NLY01, is a brain‑penetrant, long‑acting GLP‑1 receptor agonist that showed neuroprotective effects in preclinical models, including inhibition of microglial activation, prevention of neuronal death, slowed disease progression, improved motor and cognitive function, and extended lifespan in Parkinson’s models. NLY01 leverages a GLP‑1R class safety profile documented by approved diabetes treatments, and Neuraly expected to initiate a Phase 1 clinical trial in 2018. The company was formed in 2016 based on Johns Hopkins research and holds exclusive licenses to related patents; supporting data were published in Nature Medicine. Neuraly also reports two additional early‑stage pipeline candidates targeting complementary mechanisms. The company launched alongside a Series A financing to fund clinical development.